Gain Therapeutics (GANX) Current Assets (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Current Assets of $18.2 million for Q1 2026, up 63.4% year-over-year from $11.2 million in Q1 2025, and down 18.06% quarter-over-quarter from $22.2 million in Q4 2025.
Gain Therapeutics (GANX) Current Assets (2020 - 2026) Analysis & Trends
Gain Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $18.2 million for Q1 2026.
- In Q1 2026, Current Assets rose 63.4% year-over-year to $18.2 million; the TTM figure through Mar 2026 stood at $18.2 million (up 63.4% YoY), while the FY2025 annual figure was $22.2 million, up 91.66% from the prior year.
- Current Assets for Q1 2026 stood at $18.2 million, down from $22.2 million in the prior quarter.
- The five-year high for Current Assets was $36.4 million in Q1 2022, with the low at $9.3 million in Q2 2025.
- The 5-year median for Current Assets is $17.8 million (2023), against an average of $17.9 million.
- Peak annual rise in Current Assets reached 91.66% in 2025, while the deepest fall reached 49.8% in 2025.
- Gain Therapeutics' Current Assets stood at $21.1 million in 2022, then fell by 15.71% to $17.8 million in 2023, then plunged by 34.74% to $11.6 million in 2024, then surged by 91.66% to $22.2 million in 2025, then decreased by 18.06% to $18.2 million in 2026.
- Business Quant data shows GANX's Current Assets at $18.2 million in Q1 2026, $22.2 million in Q4 2025, and $10.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Gain Therapeutics | 85.12 Mn | 85.12 Mn | - | 14.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.97 Mn |
| Mar 31, 2026 | 18.22 Mn |
| Dec 31, 2025 | 22.24 Mn |
| Sep 30, 2025 | 10.52 Mn |
| Jun 30, 2025 | 9.31 Mn |
| Mar 31, 2025 | 11.15 Mn |
| Dec 31, 2024 | 11.60 Mn |
| Sep 30, 2024 | 13.74 Mn |
| Jun 30, 2024 | 18.54 Mn |
| Mar 31, 2024 | 13.86 Mn |
| Dec 31, 2023 | 17.78 Mn |
| Sep 30, 2023 | 13.24 Mn |
| Jun 30, 2023 | 17.31 Mn |
| Mar 31, 2023 | 19.32 Mn |
| Dec 31, 2022 | 21.09 Mn |
| Sep 30, 2022 | 24.35 Mn |
| Jun 30, 2022 | 25.83 Mn |
| Mar 31, 2022 | 36.39 Mn |
| Dec 31, 2021 | 37.72 Mn |
| Sep 30, 2021 | 41.55 Mn |